Study warns emodepside formulations aren't interchangeable in dogs

Version 2

A newly published AJVR study is giving veterinarians a clearer answer on a question that has hovered over rescue treatment for drug-resistant canine hookworms: can the FDA-approved feline topical emodepside formulation stand in for the canine oral product used elsewhere? The answer, based on pharmacokinetic testing in dogs, is no. Researchers reported that the feline topical solution given orally at 1 mg/kg was not bioequivalent to the European canine modified-release tablet at the same dose, and that topical administration in dogs resulted in far lower drug exposure than oral dosing. (pubmed.ncbi.nlm.nih.gov)

The issue has become more pressing as multianthelmintic drug-resistant Ancylostoma caninum has moved from a greyhound-associated concern to a broader clinical problem in U.S. dogs. An AAVP position paper published in 2025 said emodepside is not registered for dogs in the U.S. or Canada, but has been used extra-label as rescue therapy in cases that cannot be resolved with available anthelmintics. That same paper emphasized several unresolved questions, including the fact that the cat product is designed for topical, not oral, administration, even though it is being dosed orally in some resistant-hookworm cases because topical use does not work in dogs. (sciencedirect.com)

In the new study, seven healthy client-owned dogs were enrolled in a crossover design between May and August 2023. Dogs received emodepside in three ways: the feline topical solution orally at 1 mg/kg, the canine modified-release tablet orally at 1 mg/kg, and the feline topical solution topically at 3 mg/kg. Plasma drug levels were tracked for 21 days. Oral administration of the feline topical product led to markedly greater absorption than the canine oral tablet, failing bioequivalence testing, while topical administration of the feline product produced plasma concentrations 36- to 122-fold lower than oral administration. The authors said the higher oral absorption raises potential safety concerns for extra-label use in dogs, and the poor topical absorption suggests topical use is unsuitable for treating resistant hookworm infections. (pubmed.ncbi.nlm.nih.gov)

That pharmacokinetic signal lines up with earlier field and practice guidance. Clinician’s Brief has advised that the feline emodepside product has no efficacy in dogs when administered topically and must be given orally if used at all for resistant hookworms. The same guidance stressed that drug formulation affects both pharmacokinetics and safety, and that excipients in topical products are not intended for oral use. It also recommended that extra-label emodepside be reserved for cases where failure of triple-drug therapy has been confirmed, with careful dose calculation and in-clinic administration. (cliniciansbrief.com)

Expert commentary has also focused on safety and patient selection. In AAHA’s coverage, Cassan N. Pulaski, DVM, MPH, PhD, said emodepside can sometimes be the only drug that works in these cases, but highlighted important risks: rapid kill of heartworms could increase the risk of anaphylaxis in heartworm-positive dogs, and dogs with MDR1 gene variants may face higher risk of severe adverse effects, especially if dosing is inaccurate. She recommended fecal PCR testing for resistance markers before moving to extra-label emodepside, and emphasized close monitoring and clear communication with pet parents about the extra-label nature of treatment. (aaha.org)

Why it matters: For veterinarians, the study is less about whether emodepside has a role and more about how narrow that role may need to be. Resistant hookworm cases can leave clinicians with few effective options, and emodepside has been one of the few agents with evidence of activity when other classes fail. But this paper reinforces that clinicians cannot treat “same active ingredient” as shorthand for “same clinical behavior.” Formulation-level differences changed exposure substantially, which affects both efficacy expectations and safety margins. In practical terms, that supports a more conservative approach: confirm resistance, rule out heartworm infection, consider MDR1 status where relevant, calculate doses precisely, and avoid assuming topical application in dogs will provide meaningful therapeutic exposure. (pubmed.ncbi.nlm.nih.gov)

There’s also a regulatory and stewardship angle. Because no canine-labeled oral emodepside product is approved in the U.S., clinicians are operating within extra-label frameworks and the constraints of AMDUCA when they reach for the feline product in dogs. The more evidence accumulates that the formulations are not interchangeable, the harder it becomes to justify casual extrapolation from one market or label to another. That could increase pressure for clearer consensus guidance, more formal safety work in dogs, and potentially future commercial or regulatory interest in a canine oral pathway if demand persists. (vtechworks.lib.vt.edu)

What to watch: The next step is whether these pharmacokinetic findings translate into updated clinical recommendations for suspected resistant hookworm cases, and whether future studies better define safety in heartworm-positive dogs, MDR1-variant dogs, and real-world rescue-treatment protocols. (aaha.org)